Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;96(6):e29771.
doi: 10.1002/jmv.29771.

Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions

Abinash Mallick  1 , Soumi Sukla  2 , Abhishek De  3 , Subhajit Biswas  1   4
Affiliations

Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions

Abinash Mallick et al. J Med Virol. 2024 Jun.

Abstract

COVID-19 tended to be less aggressive in dengue endemic regions. Conversely, dengue cases plummeted in dengue endemic zones during the active years of the pandemic (2020-2021). We and others have demonstrated serological cross-reactivity between these two viruses of different families. We further demonstrated that COVID-19 serum samples that were cross-reactive in dengue virus (DV) serological tests, "cross-neutralized" all DV serotypes in Huh7 cells. Here we showed by co-immunoprecipitation (Co-IP) and atomic force microscopy (AFM) imaging that severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 (SARS-CoV-2) spike (S) protein subunit S1 and S2 monoclonal antibodies can indeed, bind to DV particles. Likewise, DV envelope antibodies (DV E Abs) showed high docking frequency with other human pathogenic beta-CoVs and murine hepatitis virus-1 (MHV-1). SARS-CoV-2 Ab didn't show docking or Co-IP with MHV-1 supporting poor cross-protection among CoVs. DV E Abs showed binding to MHV-1 (AFM, Co-IP, and immunofluorescence) and prepandemic dengue patients' serum samples even "cross-neutralized" MHV-1 plaques in cell culture. Furthermore, dengue serum samples showed marked inhibition potential in a surrogate virus-based competitive enzyme-linked immunosorbent assay, used for determining neutralizing Abs against SARS-CoV-2 S protein receptor-binding domain in COVID-19 serum samples. We therefore, provide multiple evidence as to why CoVs are epidemiologically less prevalent in highly dengue endemic regions globally.

Keywords: COVID‐19; SARS‐CoV‐2; antibody cross‐reactivity; dengue; virus neutralization.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Sukla S, Biswas S. COVID‐19 virus infection and transmission are observably less in highly dengue‐endemic countries: is pre‐exposure to dengue virus protective against COVID‐19 severity and mortality? Will the reverse scenario be true? Clin Exp Investig. 2020;2020(2):1‐5.
    1. Dutta D, Ghosh A, Dutta C, Sukla S, Biswas S. Cross‐reactivity of SARS‐CoV‐2 with other pathogens, especially dengue virus: a historical perspective. J Med Virol. 2023;95(2):e28557.
    1. Nath H, Mallick A, Roy S, et al. Archived dengue serum samples produced false‐positive results in SARS‐CoV‐2 lateral flow‐based rapid antibody tests. J Med Microbiol. 2021;70(6):001369.
    1. Nath H, Mallick A, Roy S, et al. COVID‐19 serum can be cross‐reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test. Int J Infect Dis. 2022;122:576‐584.
    1. Lustig Y, Keler S, Kolodny R, et al. Potential antigenic cross‐reactivity between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and dengue viruses. Clin Infect Dis. 2021;73(7):e2444‐e2449.

LinkOut - more resources

-